ABSTRACT
Acanthamoeba keratitis is an uncommon but potentially devastating complication of contact lens wear. We present a case of Acanthamoeba keratitis in a soft-contact-lens wearer successfully treated with long-term medical therapy and penetrating keratoplasty. To our knowledge this is the first case of Acanthamoeba keratitis diagnosed in Canada.
Subject(s)
Acanthamoeba Keratitis/etiology , Contact Lenses, Hydrophilic/adverse effects , Acanthamoeba/isolation & purification , Acanthamoeba Keratitis/drug therapy , Acanthamoeba Keratitis/pathology , Acanthamoeba Keratitis/surgery , Adult , Animals , Antiprotozoal Agents/therapeutic use , Benzamidines/therapeutic use , Female , Humans , Keratoplasty, Penetrating , Ketoconazole/therapeutic use , Visual AcuityABSTRACT
Cyclosporin A given to rabbits intramuscularly in a dose of 25 mg/kg/day for up to 28 days after corneal transfer results in a marked prolongation in the survival of penetrating corneal grafts compared to that in an untreated control group. Cyclosporin A 1% drops did not prolong survival of the corneal graft, but this may be related to the need for skin transfer 14 days after corneal transfer to ensure rejection, and supports the idea that the drug plays an immunosuppressive role at the time and place of sensitisation.
